won't set optional cookies unless you enable them. Using this tool will set a cookie on your device to remember your preferences. For more detailed information about the cookies we use, please see our
subscribers increased 41% QoQ to stand at 5.5mn from efforts to encourage 5G adoption through affordable 5G packages and device bundling. AIS Fibre continued surging and closed 3Q22 at 2.1mn with net increase
enhanced device margin. AIS reported a net profit of Bt8,788mn, increasing 7.9% YoY reflecting strong operating performance, while increasing 2.5% QoQ from higher foreign exchange rate gain. 3Q24 MD&A
as the first year of the second phase of the long-term strategy where the Company expects the leap and sustainable growth. The Company will be able to start getting benefits from the past 3 year
ปฏิบัติงำนท่ีมีกำรใช้อุปกรณ์เคลื่อนท่ี (mobile device) เพื่อเข้ำถึงระบบสำรสนเทศภำยในองค์กร และกำรปฏิบัติงำนจำกภำยนอกบริษัท (teleworking) 3.1 กรณีพนักงานท าการเชื่อมต่อ remote access จากที่บ้าน ผู้ประกอบ
, medical device business is expected to be growth at an average rate of 8.5-10.0% per year. This growth will be supported by: (i) government policy, focused on promoting investment in the sector through the
1,921 million decreased by 7% compared to the previous year. It derived from: • Revenues from sales and services of medical device business for the year 2019 were Baht 1,798 million decreased by 3% in
(minute/s Postpaid Prepaid Blended VOU (GB/data s Postpaid Prepaid Blended Device Penetrat 4G‐handset Fixed Broadban FBB subscri FBB net add FBB ARPU ( 1H17 Snap For 1H17, AIS (excluding IC
% -2.4% Prepaid 113 92 86 -24% -6.5% Blended 138 118 112 -19% -5.1% VOU (GB/data sub/month) Postpaid 14.4 16.6 17.0 18% 2.3% Prepaid 10.3 11.1 13.8 34% 23% Blended 11.4 12.7 14.7 29% 16% Device Penetration
appropriate by Dhipaya Bodin as a joint venture. It will benefit potential shareholders in the medical device and distribution business. The current production and distribution line is Blood Line with a